

Drug Utilization Review Board**Date: February 17, 2021****Time: 9 a.m. to 4 p.m.****GoTo Webinar**

9 a.m.	Welcome & Introductions Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Ginni Buccola, Committee Chair
9:05 a.m.	Antibiotics: Aminoglycosides-inhaled, and Monobactams-inhaled <ul style="list-style-type: none"> Stakeholder input* Motion 	Umang Patel, Magellan
9:08 a.m.	Respiratory agents: Cystic Fibrosis agents <ul style="list-style-type: none"> Stakeholder input* Motion 	Umang Patel, Magellan
9:18 a.m.	Anticoagulants: Factor XA and Thrombin Inhibitors-oral <ul style="list-style-type: none"> Stakeholder input* Motion 	Umang Patel, Magellan
9:30 a.m.	Antidiabetics: Amylin analogs, DPP4 Inhibitors, SGLT2, SGLT2 combos, TZD combos, GLP1 agonist, Insulin combos <ul style="list-style-type: none"> Stakeholder input* Motion 	Umang Patel, Magellan
9:55 a.m.	Antidiabetics: Insulin <ul style="list-style-type: none"> Stakeholder input* Motion 	Umang Patel, Magellan
10:10 a.m.	Endocrine and Metabolic Agents: Growth Hormone Releasing Hormones (GHRH) <ul style="list-style-type: none"> Stakeholder input* Motion 	Umang Patel, Magellan
10:18 a.m.	Endocrine and Metabolic Agents: Growth Hormones <ul style="list-style-type: none"> Stakeholder input* Motion 	Umang Patel, Magellan
10:25 a.m.	Gastrointestinal Agents: Inflammatory Bowel Agents <ul style="list-style-type: none"> Stakeholder input* Motion 	Umang Patel, Magellan
10:35 a.m.	Break	All
10:45 a.m.	Apple Health Archived Drug Classes	Marissa Tabile, HCA
12 p.m.	Lunch	All
12:30 p.m.	Apple Health Archived Drug Classes continued	Marissa Tabile, HCA
2 p.m.	Break	All
2:10 p.m.	Apple Health Archived Drug Classes continued <ul style="list-style-type: none"> Stakeholder input* Motion 	Marissa Tabile, HCA
3:40 p.m.	Apple Health Policy: Pulmonary Hypertension Agents <ul style="list-style-type: none"> Stakeholder input* Motion 	Marissa Tabile, HCA

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

4:00

Drug Utilization Review Board Adjourns

Ginni Buccola,
Committee Chair

For all Apple Health (Medicaid) questions, please email AppleHealthPharmacyPolicy@hca.wa.gov.

** Stakeholders will be allowed 3 minutes for comments.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions
please call Leta Evaskus at 206-521-2029.